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The purpose of this study was to investigate the effects of hydroxytyrosol (HT) 
supplementation on markers of mitochondrial biogenesis, aerobic capacity, and endurance 
exercise performance in recreationally active men.  Sixty-one (n = 61) subjects (21.46 ± 0.22 yrs, 
179.46 ± 0.79 cm, 78.91 ± 1.19 kg) consumed either a high dose (HI) HT supplement (150 mg HT), 
a low dose (LO)  HT supplement (50 mg HT), or a placebo (PLA) every day for 6 weeks.  
Muscle biopsies from the vastus lateralis were obtained at baseline and after 6 weeks of 
supplement consumption and analyzed for markers of mitochondrial biogenesis: succinate 
dehydrogenase (SDH), citrate synthase (CS), and peroxisome proliferator-activated receptor ɣ 
coactivator (PGC)-1α.  Subjects completed exercise testing on a bicycle ergometer at baseline 
and after 3 and 6 weeks of supplement consumption to measure changes in maximal aerobic 
vi 
 
power (VO2MAX), lactate threshold, respiratory exchange ratio (RER), substrate utilization, and 
endurance exercise performance on a 20 km time trial course.  The primary findings were that 
HT supplementation increased muscle oxidative enzyme activity suggesting increased oxidative 
capacity.  HT also increased time trial performance at midpoint and endpoint and this 
corresponded with an improvement in lactate threshold and a lower RER for the LO HT 
treatment.  Time trial performance was also improved at endpoint for PLA, however, unlike LO 
an HI HT, this was accompanied by a significant increase in rating of perceived exercise (RPE) 
and not associated with improvements in muscle oxidative capacity.  Our results indicate that HT 
ranging from 50 to 150 mg/day for 6 weeks can improve muscle oxidative capacity and aerobic 
performance, and suggests that HT may be used chronically to improve mitochondrial function.   
HT may be used as an effective means to increase mitochondria to improve exercise 
performance, and limit diseases associated with mitochondrial dysfunction such as 
cardiovascular disease, type II diabetes, and some cancers. 
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Adherence to a Mediterranean diet may improve longevity and reduce the risk of diseases 
associated with mitochondrial dysfunction and aging, such as cardiovascular disease, type II 
diabetes, and cancer (Trichopoulou et al., 2003).  It appears that hydroxytyrosol (HT) (Figure 1), 
a polyphenolic component of extra virgin olive oil, is partly responsible for these health benefits 
(Granados et al., 2010; Paiva-Martins et al., 2011).  HT appears to exert its beneficial effects by 
increasing mitochondrial biogenesis and function inside the cell via the activation of 5‘-AMP 
activated protein kinase (AMPK) and downstream transcription factor peroxisome proliferator-
activated receptor ɣ coactivator (PGC)-1α (Hao et al., 2009; Zhu et al., 2010).  The protective 
effects of HT have been clearly demonstrated in vitro and in animal models, but there is no 
research to-date showing HT-induced mitochondrial biogenesis in humans. 
Most investigators agree that HT is biologically available to humans upon ingestion 
(Visioli et al., 2000; Pinto et al., 2006); however it is debated whether the amount of HT required 
to elicit its potential biological activities can be practically achieved in humans (Vissers et al., 
2004; Khymenets et al., 2010).  HT treatment of isolated cells at concentrations of as little as 1 
µmol/L increased the expression of mitochondrial complexes I through IV in isolated adipocytes.  
These increases in mitochondrial complex protein expression were approximately 1.5- to 1.7-
fold compared to control samples (Hao et al., 2009).  HT administered to rats at a concentration 
of 0.5 mg/kg body weight 5 days per week for 6 weeks altered expression of genes related to 
apoptosis, cell cycle, proliferation, differentiation, survival and transformation pathways 
(Granados et al., 2011).  Data from an unpublished HT supplementation study showed a 
significant difference on measured metabolic markers between placebo and 200 mg HT up to 90 
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minutes after supplementation with an observed effect size of .7 at 60 minutes and .85 at 30 min.  
Based on these findings, we sought to determine whether HT-induced mitochondrial biogenesis 
and improved endurance exercise performance could be demonstrated in humans. 
Therefore, the purpose of this study was threefold: 1) to investigate if regular daily HT 
supplementation would increase markers of MT biogenesis and density in skeletal muscle: 
succinate dehydrogenase (SDH), citrate synthase (CS), and PGC-1α; 2) to determine if regular 
daily HT supplementation would increase maximal aerobic power (VO2MAX), lactate threshold 
(LT), and endurance exercise time trial performance; and 3) to determine whether a regular high-
dose (HI) HT supplement (150 mg/day) affects skeletal muscle markers of aerobic metabolism, 
VO2MAX, LT, and time trial performance differently than a regular low-dose (LO) HT 
supplement (50 mg/day).  All research was conducted on recreationally active, healthy males 







This study was a double-blinded, parallel, randomized placebo-controlled study.    
Subjects consumed daily supplementation of a high dose (HI) of HT (150mg), a low dose (LO) 
of HT (50mg), or a placebo (PL) in capsule form for six weeks.  Subjects refrained from 
consumption of specific foods including olive oil that contain high levels of antioxidants or 
polyphenols throughout the course of the study.  Subjects were encouraged to maintain normal 
dietary and exercise habits.   
Specific proteins related to mitochondrial biogenesis and function (SDH, CS, and PGC-
1α) were measured directly by muscle biopsies at baseline and endpoint.  Maximal aerobic 
capacity was determined by a VO2MAX test on a bicycle ergometer at baseline, midpoint, and 
endpoint.  Additionally, subjects completed a lactate threshold test as an indicator of aerobic 
capacity and exercise performance at baseline, midpoint, and endpoint.  RER was measured 
during steady state exercise at baseline, midpoint, and endpoint to determine if there was a shift 
in substrate utilization at 65% of VO2MAX over the course of the study.  Endurance exercise 
performance, measured as time to complete a 20 km time trial on a bicycle ergometer, was also 




A total of 61 subjects were enrolled in this study: 3 groups, n = 19, 20, and 22.  
Recreationally active men between 20 and 35 years of age were recruited from The University of 
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Texas at Austin and the Austin, Texas community. Investigators posted flyers in UT buildings to 
recruit subjects from UT faculty, staff and students, and advertisements were posted on internet 
job databases to recruit additional subjects from the Austin, Texas community.  Refer to Table 1 
for detailed subject characteristics. 
This study was approved by the Institutional Review Board at The University of Texas at 
Austin prior to any subject recruitment or screening procedures.  Upon an initial phone 
consultation, the individual came into the Fitness Institute of Texas (FIT), Bellmont Hall, The 
University of Texas at Austin.  A detailed explanation of the experimental procedures and the 
potential risks of the study were given both verbally and in writing to all subjects.  Subjects were 
given the opportunity to ask questions before signing the informed consent, according to the 
protocol described in the University of Texas at Austin‘s ‗Institutional Review Board Procedures 
Manual for Faculty, Staff and Student Researchers with Human Subjects‘.  All potential subjects 
gave informed consent in writing prior to any biomedical research project-specific procedures. 
After the informed consent was signed, the potential subject completed the Participation 
Health Research Screening Form.  The volunteer was only invited to participate in the study if 
he answered ―no‖ to questions on the Participation Health Research Screening Form pertaining 
to hypertension, circulatory, liver and kidney conditions and diabetes.  Allergy, anti-depressant, 
and thyroid medications were acceptable only if the dosage had been constant for at least 2 
months leading up to the screening. The potential subject was excluded if he was taking 
medication to treat cardiac, lipid, or hypertensive conditions or to control blood glucose. 




 Measurement of weight, height, and calculation of body mass index (BMI).  To be 
included in the study, BMI must have been less than 30 at the time of screening. 
 Completion of the Participation Health Research Screening Form 
 Review of medical history, medications and any dietary supplements that the potential 
subject was using at the time of screening 
 Measurement of blood pressure.  To be included in this study, blood pressure must have 
been lower than or equal to 140/90 mmHg at the time of screening. 
 
If the potential subject qualified to participate in this study based on the results of the 




 HT is generally recognized as safe and non-toxic (Edwards et al., 2009).  The study 
supplement was manufactured by DSM Nutritional Products (Kaiseraugst, Switzerland) through 
a purification process of waste water from olive oil processing.  This protocol attempted to show 
the lowest efficacious chronic dose over 6 weeks in men consuming 50 mg HT per day. The high 
dose of 150 mg is slightly lower than the dose (200 mg pure extract) that has been used in a 
previous human study by Rietjens et al. (2011) and falls within acceptable daily intake (ADI) 
recommendations (Edwards et al., 2009). 
 Following is a description of the study supplement composition: 
 Placebo (PLA): 0mg HT—3 capsules with each 333mg of modified starch 
 Low-dose HT (LO): 50mg HT—1 capsule with each 333mg investigational product 
(50mg hydroxytyrosol) and 2 capsules with each 333mg modified starch 
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 High-dose HT (HI): 150mg HT—3 capsules with each 333mg investigational product 
(50mg hydroxytyrosol) 
 
On the day of the baseline steady-state time trial test, each subject was randomly assigned to 
receive one of three double-blinded supplements: PLA (n=19), LO (n=20), or HI (n=22).  
Randomization was performed by Metronomia (Muenchen, Germany).  Group assignments 
attempted to evenly distribute subjects by weight: if a subject entered the trial and weighed less 
than 80 kg, the lowest available medication number was assigned.  If a subject entered the trial 
and weighed 80 kg or more, the highest available medication number was assigned.   
Each subject was instructed to keep the supplement refrigerated at all times, and to consume 
3 capsules at home in the morning with breakfast each day for the remainder of the study.  On 
the days that the subject was scheduled to come to the laboratory for the endpoint muscle biopsy, 
he was instructed to consume that day‘s supplement at home precisely 1.5 hr before his 
appointment time.  On the days that the subject was scheduled to come to the laboratory for an 
LT/VO2MAX or SS/TT test, he was instructed to not consume that day‘s supplement at home; 
instead he was to bring the supplement into the laboratory and consume it in the laboratory under 
the supervision of a researcher.  The time of supplement consumption was recorded, and exercise 
testing began 30 min from the time the supplement was consumed.   
If the subject failed to consume a daily supplement dose by 2:00 PM for any reason, he 
was instructed to not consume that dose, and to leave the dose and its packaging intact in the 
box.  The subject was instructed to return the empty and full supplement packaging to the 
laboratory at his first blood draw visit.  The subject was allowed to miss no more than one dose 
per week and must have been at least 85% compliant (must have consumed at least 36 out of 42 
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provided supplement doses) over the entire study period.  All study subjects met the minimum 
supplementation compliance requirements. 
 
Dietary and Exercise Regimen 
 
Each subject was required to refrain from consumption of foods or supplements 
containing high levels of antioxidants or polyphenols throughout the course of the study.  
Subjects were limited to 1 tbsp of olive oil per day, 1 cup of coffee or tea per day, 2 glasses of 
wine per week, and 2 chocolate bars per week.   
The subject was required to avoid consuming coffee, tea, chocolate, wine, cherry 
tomatoes, broccoli, blueberries, and onions for at least 24 hr prior to each series of laboratory 
testing and on each day of laboratory testing, and to meet fasting requirements for each specific 
visit.   
Additionally, the subject was required to avoid performing strenuous exercise beginning 24 
hr prior to each series of laboratory testing (baseline, midpoint, and endpoint) and safety blood 
draw, and on each day of laboratory testing, with the exception of exercise performed in the 
laboratory as part of the study protocol.   
Otherwise, the subject was required to maintain normal dietary and exercise habits over the 
course of the study.  The subject was required to complete food/medication/exercise logs 
beginning 2 days prior to each series of laboratory testing (baseline, midpoint, and endpoint) and 
on each day of laboratory testing and to replicate his baseline diet and exercise for his subsequent 
midpoint and endpoint visits. 
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Daily Log Procedures  
 
Each subject maintained a daily online log (Zoomerang, San Francisco, CA), in which he 
reported the time that he consumed his supplement each day, any exercise performed on the 
previous day, and any adverse events that may have occurred since the previous day.  The log 
also contained a series of questions surveying his overall emotional and physical well-being for 
that day using a condensed version of the Profile of Mood States (POMS) scale (McNair and 
Droppelman, 1971).  If the subject had not completed the log by 6:00 PM, he received a 
reminder to complete the log. 
 
Subject Health and Safety Procedures 
 
At each study visit, any newly occurring illnesses diseases or illnesses experienced by the 
subject that had worsened since the previous visit and any medications taken by the subject since 
the previous visit were documented by a researcher and reviewed by the study physician.  If the 
study physician deemed that the subject‘s health might be in danger by continuing the study, or if 
the subject‘s condition or medication might interfere with the study results, the subject was 




Familiarization occurred after the subject had met screening criteria and had signed the 
Informed Consent Form, and approximately 1 week prior to baseline testing.  The purpose of the 
familiarization was to screen the subject for hepatitis B and C, as well as to allow the subject to 
9 
 
become accustomed to riding the bicycle ergometer and breathing though a Daniel‘s valve, and 
to acclimate to the time trial course, all of which would be utilized for experimental testing in 
subsequent visits.  This trial simulated the experimental protocol, exclusive of a full-length 
steady state ride and blood draws. 
For the familiarization, the subject reported to the Exercise Physiology and Metabolism 
Laboratory, Bellmont Hall, The University of Texas at Austin after a 2-hr fast, during which only 
water was consumed.  If the subject met dietary and health compliance criteria, a researcher drew 
4 ml of blood from a forearm vein, and the blood was sent to an outside diagnostic laboratory 
(Quest Diagnostics, Irving, TX) to be screened for hepatitis B and C.  All subjects in this study 
tested negative for hepatitis B and C. 
The subject‘s weight was measured and recorded, and the subject was fitted with a heart 
rate monitor (Cardiosport, Waterlooville, Hampshire, ENG) attached to an elastic strap around 
his chest, which communicated with a wrist receiver held by a researcher.  The subject was given 
instructions regarding the SS/TT familiarization ride, which was similar to the subsequent SS/TT 
experimental rides.  All exercise testing throughout the study was performed on a bicycle 
ergometer (VelotronDynafit Pro, Racermate, Seattle, WA; Velotron Coaching Software (CS) 
2008, Version 1.6.458, Racermate Inc., Seattle, WA) equipped with an adjustable seat, adjustable 
handlebars, and pedals with straps to secure the subject‘s feet.  The bicycle ergometer was fitted 
to the subject and the settings were recorded.  The subject was equipped with a Daniel‘s valve 
which was connected to a computer-based metabolic system (ParvoMedics TrueOne 2400 
(Sandy, UT)).  This metabolic system was used throughout the study to calculate VO2, VCO2 and 
respiratory exchange ratio (RER).  The metabolic system was calibrated prior to each testing 
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session.  As a warm-up, the subject rode for 5 min at 65% of his estimated maximum heart rate 
(HRMAX), based on the following regression equation (Tanaka et al., 2001):  
Estimated HRMAX (bpm) = 208 – 0.7 * Age (yrs) 
The Daniel‘s valve was removed and the subject then completed a custom 20 km time 
trial course (Velotron 3D 2008, Version 3, Racermate Inc., Seattle, WA) while being encouraged 
to complete this fixed distance as quickly as possible.  The time trial course was designed with 
intermittent rolling hills and the ergometer was equipped with a toggle to allow the subject to 
shift gears at will throughout the course to adjust to the terrain.  This time trial course was used 
for each time trial ride throughout the study.  Water was provided ad libitum.  Heart rate and 
RPE were collected at 10 km of the time trial ride, and again at 19.5 km of the time trial ride.  
Peak watts, average watts, average speed, and time to completion for the time trial ride was 
recorded.  After completing the time trial course, the subject remained on the bicycle ergometer 




Over the course of the study, two muscle biopsies were collected from the vastus lateralis 
muscle of the thigh to measure succinate dehydrogenase (SDH), citrate synthase (CS) and PGC-
1α.  The first muscle biopsy was collected at baseline before the subject was randomized and 
provided with study supplement, and the second muscle biopsy was collected at endpoint after 
the subject had regularly consumed the study supplement for 39 days.   
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The subject reported to the laboratory in the morning following a 12-hr fast, during which 
only water was consumed.  To prepare for each muscle biopsy, the subject was also instructed to 
shave both of his thighs to clear the muscle biopsy site of hair.  If the subject met diet, exercise, 
and health compliance criteria, 15 ml of blood was drawn from a forearm vein to be analyzed for 
markers of immune system function, muscle damage, and general health (refer to Appendix A - 
Safety Blood Draws). 
The subjects were then instructed to lie in a supine position on an examination table.  The 
skin of the subject‘s mid-thigh was cleaned with 10% povidone-iodine and anesthetized locally 
with an injection of 1.5 cc of 1% Lidocaine-HCL into the skin.  A 5-8 mm incision was made in 
the skin and subcutaneous fat, and approximately 100 mg of muscle tissue was removed with a 
Bergström biopsy needle (Dyna Medical, London, Ont. Canada). The incision site was sealed 
using butterfly bandages, and then the subject‘s thigh was wrapped with a pressure pack to 
minimize bruising. 
 
Lactate Threshold/VO2MAX Test 
 
The LT/VO2MAX test occurred three times over the course of the study.  The baseline 
LT/VO2MAX test was scheduled for the day after the first muscle biopsy, before the subject was 
randomized and provided with study supplement.  The midpoint LT/VO2MAX test was scheduled 
to occur after the subject had regularly consumed the study supplement for 20 days.  The 
endpoint LT/VO2MAX test was scheduled to occur the day after the last muscle biopsy, after the 
subject had regularly consumed his designated treatment for 40 days.  
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The subject reported to the laboratory following a minimum 2 hr fast, during which only 
water was consumed.  If the subject met dietary, exercise, and health compliance criteria, his 
weight was measured and recorded and he was fitted with a heart rate monitor.   
The LT/VO2MAX test was performed on the bicycle ergometer. The protocol consisted of 
a 5-min warm-up at 60 watts, followed by a 20 or 30 watt increase every 2 min until the subject‘s 
increase in VO2 was less than 0.2 L•min
-1
, or until the subject could not maintain a cadence of at 
least 60 RPM on the bicycle ergometer, or if the subject voluntarily stopped the test.  The 
protocol was determined based on the subject‘s watts at 65% HRMAX, which was measured at the 
Familiarization visit: if average watts were 150 or below, the protocol increased in 20-watt 
increments, and if average watts were above 150, the protocol increased in 30-watt increments.  
Heart rate was measured and recorded during the final 30 sec of each work stage.  During this 
test, the subject breathed through a Daniel‘s valve connected to the computer-based metabolic 




) and respiratory 
exchange ratio (RER) in 15 sec intervals for the entire test duration.  The three highest 15 sec 
values were averaged to determine VO2MAX (L O2• min
-1
). 
During the VO2MAX test, a researcher measured blood lactate by performing a finger prick 
blood collection within the final 30 seconds of each work stage. The subject‘s finger was cleaned 
with a sterile alcohol swab, allowed to dry, and pricked near the tip with a lancet. The first drop 
of blood was wiped off using sterile gauze, and the second drop was measured using the Lactate 
Pro handheld blood lactate analyzer (FaCT Canada Consulting Ltd., Quesnel British Columbia, 
Canada) and Lactate Pro test strips (ARKRAY Inc., Minami-Ku, Kyoto, Japan).  The lactate 
analyzer was calibrated prior to each test session.  Refer to Figure 3 for an illustration of the 
LT/VO2MAX test protocol. 
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Before leaving the laboratory, the subject was provided with 1 bottle of vanilla-flavored 
Ensure (Abbott Nutrition, Cleveland, OH) to drink exactly 10 hr before the steady state/time trial 
test to make certain that each subject consumed adequate calories so that lack of fuel availability 
was not a limiting factor in the strenuous time trial performance. 
 
Steady State/Time Trial Test 
 
The steady state/time trial (SS/TT) test occurred four times over the course of the study.  
The baseline SS/TT test was scheduled for the day after the baseline LT/VO2MAX test, before the 
subject was randomized and provided with study supplement.  The midpoint SS/TT test was 
scheduled for the day after the midpoint LT/VO2MAX test, after the subject had regularly 
consumed the study supplement for 21 days.  The first endpoint SS/TT test was scheduled to 
occur the day after the endpoint LT/VO2MAX test, after the subject had regularly consumed the 
study supplement for 41 days.  A second endpoint SS/TT test was scheduled for the day after the 
first endpoint SS/TT test, after the subject had regularly consumed the supplement for 42 days.  
The purpose of the second endpoint SS/TT test was to induce muscle damage and inflammation 
in the subject so that any potential protective or anti-inflammatory effects of the study 
supplement would be more conspicuous. 
To prepare for each SS/TT test, the subject was required to consume the provided bottle 
of Ensure precisely 10 hr prior to his SS/TT test.  The subject reported to the laboratory the day 
after the LT/VO2MAX test, following a 10-hr fast, during which only water was consumed.  If the 
subject met dietary, exercise, and health compliance criteria, he was fitted with a heart rate 
monitor and his weight was measured and recorded.   
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After the subject had sat quietly in a chair for 5 minutes, his resting heart rate was 
measured and recorded.  A 20-guage Teflon catheter was inserted into a forearm vein, fitted with 
a three-way stopcock, extended with a catheter-extension, and taped in place.  10 ml of blood 
was drawn while the subject was seated, just before he began the steady state test. 
The steady state test was performed on the bicycle ergometer and consisted of a 5 min 
warm-up steady state ride at watts equivalent to 50% VO2MAX, followed by a 15 min steady state 
ride at watts equivalent to 65% VO2MAX, based on the following regression equation adapted 
from Åstrand and Rodahl (1977): 
Work Rate (watts) = [VO2MAX (ml O2•min
-1
) * (%VO2MAX desired) – 300 (ml 
O2•min
-1




During this test, the subject breathed through a Daniel‘s valve connected to the computer-
based metabolic system which was used to measure average VO2, VCO2 and respiratory 
exchange ratio (RER) in 15 sec intervals during the final 10 min of the 15 min steady state period 
at 65% VO2MAX.  Carbohydrate and fat oxidation rates (g·min
-1
) were calculated from VCO2, 
VO2, and RER according to Frayn (1983).  It was assumed that protein oxidation during exercise 
was negligible. Heart rate and Borg Rating of Perceived Exertion (RPE) was collected at 4 min 
into the 5 min 50% VO2MAX steady state period and again at 10 min into the 15 min 65% 
VO2MAX steady state period.  Refer to Figure 4 for an illustration of the steady state protocol.  
Upon completion of the steady state ride, the subject was allowed to dismount from the bicycle 
ergometer and rest for a period of 5 min.   
The subject then completed the 20 km time trial while being encouraged to complete this 
fixed distance as quickly as possible. The subject was able to view and compete with his fastest 
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previous time trial performance.  Average time to complete the time trial and the fastest time to 
completion across all subjects was also posted in the laboratory as another means of externally 
motivating the subjects to perform the time trial at maximum exercise capacity.  Water was 
provided ad libitum.   0.05 ml of venous blood drawn from the forearm catheter during the time 
trial just prior to the subject‘s completion of the course (at 19.5 km) was used for analysis of 
blood lactate.  Heart rate and RPE were also collected at 10 km into the course, and again at the 
time of the end blood draw.  Peak watts, average watts, average speed, and time to completion 
for the time trial was recorded.  Refer to Figure 5 for an illustration of the time trial protocol. 
After the subject completed the time trial, he remained on the bicycle ergometer for a 
cool-down period, until his heart rate dropped below 120 bpm.  The subject then dismounted 
from the bicycle ergometer and was seated in a chair.  A research assistant removed the catheter 
from the subject‘s arm, applied sterile gauze and a bandage to the site of the catheter puncture, 
and cleaned the skin around the area with a sterile alcohol swab.  A light meal was then provided 
to the subject. 
 
Blood Tissue Analysis 
 
The blood sample collected at the end of the time trial (0.5 ml) was deposited into a 
storage tube containing 10% perchloric acid (PCA) (1 ml).  The storage tube was centrifuged at 
4˚ C for 10 min at 3,000 rpm with a HS-4 rotor in a Sorvall RC6 centrifuge (Kendro Laboratory 
Products, Newtown, CT).  The supertanant was extracted from the storage tube and transferred to 
microcentrifuge tubes, then stored at -80˚C until further analysis. 
16 
 
Blood lactate.  Blood lactate concentrations were measured from the PCA extracts using 
enzymatic analysis according to Hohorst.  Samples were read at 340 nm using a Beckman 
DU640 Spectrophometer (Coulter, Fullerton, CA). 
 
Muscle Tissue Homogenization 
 
The extracted biopsy sample was trimmed of adipose and connective tissue and 
immediately frozen in liquid nitrogen, weighed, and stored in microcetrifuge tubes at -80
o
C until 
further analysis.  
SDH and CS.  For the enzymatic analyses of SDH and CS, samples were homogenized in 
ice-cold buffer containing 0.17 M potassium phosphate (pH 7.4), 10 mM 2-mercaptoethanol 
(Sigma M6250), and 0.05% bovine serum albumin (ICN 105033) at a dilution of 1:30.  
Homogenization was performed on ice using 3 x 5 sec bursts with a size 20 tissue grinder 
(Kimble Chase, Vineland, NJ).  A portion of the homogenate was immediately used for the SDH 
assay.  The remaining homogenate was aliquoted to storage tubes and stored at -80°C for later 
analysis of CS. 
PGC-1α.  For determination of total PGC-1α content, the tissue samples were 
homogenized at a dilution of 1:10 in a modified RIPA buffer based on a previously described 
protocol (Wright et al., 2007) containing: 50 mM Tris-HCL (pH 7.4); 150 mM NaCl (pH 7.4); 
1% each Igepal CA-630 and sodium deoxycholate; 1 mM each EDTA (pH 7.4), Na3VO4  (pH 
10), NaF, and phenylmethylsulfonyl fluoride; 1 µg/ml each aprotinin, leupeptin and pepstatin.  
Homogenization was performed on ice using 4 bursts of 5 sec each with a Caframo RZRl Stirrer 
(Caframo Limited, Warton, Ontario, Canada).  The homogenates were sonicated on ice for 10 
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sec and then centrifuged at 5,000 g for 20 min at 4°C.  The supernatant was aliquoted to storage 
tubes and stored at -80°C for later analysis of PGC-1α.  
 
Muscle Tissue Analysis 
 
 SDH.  SDH content was determined according to the method of Lowry and Passonneau 
(1972).  The amount of NADH produced during a 5 min incubation time was read on a Varian 
Cary Eclipse fluorometer with an excitation wavelength of 340 nm and emission wavelength of 
450 nm (Varian, Inc., Palo Alto, CA) and corresponded to SDH activity in the sample.  SDH 
activity was expressed as µmols/g/min protein. 
CS.  CS activity was determined according to the protocol of Srere (1969) on the 
homogenates after further dilution of 1:10 (wt/vol) with 0.1 M Tris-HCI and 0.4% Triton X-100 
buffer (pH 8.3).  The rate of appearance of DTNB was determined spectrophotometrically over 5 
min at 412 nm and 37
o
 C using a Beckman DU 640 spectrophotometer (Fullerton, CA), and was 
proportional to CS activity.  CS activity was expressed as µmols/g/min protein. 
PGC-1α.  PGC-1α content was determined by Western blotting. Total α-tubulin content 
was also determined as a housekeeping protein.  Aliquots of homogenized muscle sample 
supernatants and standards were slowly thawed over ice and diluted 1:1 with sample buffer 
containing 1.25M Tris, pH 6.8, glycerol, 20% SDS, 2-mercaptoethanol, 0.25% bromophenol 
blue solution, and deionized water.  Samples containing 100 µg of total protein were separated 
on 10% polyacrylamide gels by SDS-PAGE for 80 min at 185 V (Bio-Rad Laboratories, 
Hercules, CA.)  After electrophoresis, the gels were electrotransferred using a wet transfer cell 
(Bio-Rad Laboratories, Hercules, CA.) using 90 V for 90 min to 0.4 µm polyvinylidine fluoride 
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(PVDF) membranes (Millipore, Bedford, MA).  The membranes were blocked in TTBS (TBS, 
50 mM Tris, 150 mM NaCl, containing 0.1% Tween-20), and 10% nonfat dry milk for 20 min at 
room temperature on a rocking platform at medium speed.  The membranes were then washed in 
1x TTBS 3 times for 5 min each wash.  Using the molecular weight markers visible on the 
membranes as a guide, the membranes were cut at the 75 kD marker.  The upper section was 
used for detection of PGC-1α, and the lower section was used to detect α-tubulin.  Each 
membrane section was incubated overnight at 4°C on a rocking platform at low speed with 
antibodies directed against PGC-1α (no. 515667, EMD Calbiotech/Merck KGaA, Darmstadt, 
Germany), and α-tubulin (no. 2144, Cell Signaling, Danvers, MA).  The antibodies were diluted 
1:1000 for PGC-1α, and 1:900 for α-tubulin in TTBS containing 2% nonfat dry milk.  Following 
the overnight incubation, membranes were washed three times with TTBS for 5 min each wash 
and incubated for 60 min with a secondary antibody (goat anti-rabbit, HRP-linked IgG, no. 7074, 
Cell Signaling, Danvers, MA).  Dilutions were 1:900 for PGC-1α and 1:900 for α-tubulin.  The 
immunoblots were visualized by enhanced chemiluminescence (Perkin Elmer, Boston, MA) 
using a Bio-Rad ChemiDoc detection system, and the mean density of each band was quantified 
using Quantity One 1-D Analysis software (Bio-Rad Laboratories, Hercules, CA.).   A molecular 
weight ladder (Precision Plus Protein Standard, Bio-Rad) and a rodent internal control standard 
prepared from insulin-stimulated mixed skeletal muscle were also included on each gel.  All 
blots were compared with the rodent control standard and the values of each sample were 






A power analysis was performed using G*Power3 (Faul et al., 2003) on the primary 
outcome parameter, Trolox equivalent antioxidant capacity (TEAC), to determine the number of 
subjects per group.  Data from an HT supplementation study (Rietjens et al., 2011) showed a 
significant difference on measured metabolic markers between placebo and 200mg HT up to 90 
minutes after supplementation with an observed effect size of .7 at 60 minutes and .85 at 30 
minutes.  Assuming a power of .8 and alpha =.05, and one tail, the sample size was estimated to 
be 20 subjects per group for 3 independent groups. 
Statistical analysis of the data was performed using PASW 18.0 for Windows (SPSS Inc., 
Chicago, IL).  A Levene test was performed to verify that variance was equal across groups.  All 
overall within treatment (baseline, midpoint, and endpoint) variables were measured using 
repeated measures ANOVA.  When significance was found, post hoc comparisons were 
performed using an LSD treatment with a manual adjustment to correct for positively-biased F 
values.  Mean differences within treatments between timepoints were compared using paired-
samples t-tests.  A two-tailed Pearson correlation analysis was performed on the changes from 
baseline to endpoint in all variables across each treatment group.  Differences were considered 







SDH increased from baseline to endpoint within the HI treatment group by 9.4% (p<.05).  
SDH increased from baseline to endpoint within the LO treatment group by 9.6% and decreased 
in the PLA group by 1.3%, although neither change was significant.  There were no significant 
overall time or treatment effects, nor was there a significant time by treatment interaction 
(Figure 6).  
 
CS 
CS increased from baseline to endpoint within the LO treatment group by 13.6% (p<.05) 
and within the HI treatment group by 17.8% (p<.01).  CS increased in the PLA group by 1.0%, 
although this difference was not significant.  There was a significant overall time effect.  There 




There were no significant changes in PGC-1α within treatments over time, nor was there 
a significant overall time effect (p=.056), although all treatment groups increased from baseline 
to endpoint.  There was no significant overall treatment effect, nor was there a time by treatment 
interaction (Figure 8).   
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α-tubulin was measured as a housekeeping protein of PGC-1α.  There was no significant 




There was no significant overall treatment effect, nor a significant time by treatment 
interaction for VO2MAX.  Although VO2MAX was significantly increased in the LO group from 
baseline to midpoint (p<.05) and from baseline to endpoint (p<.01), the magnitude of change was 
not physiologically relevant.  There was a significant overall time effect (p<.05), with VO2MAX 




VO2 at lactate threshold increased from baseline to midpoint (p<.05) and from baseline to 
endpoint (p<.01) in the LO treatment group.  Lactate threshold did not change over time in the 
PLA or HI treatment groups.  There was a significant overall time effect (p<.05) and treatment 
by time interaction (p<.01).  There was no significant overall treatment effect (Figure 11).  The 
change in lactate threshold was positively correlated with the change in VO2MAX (r =.306; p<.05), 
such as when VO2MAX increased, lactate threshold increased. 
 
RER at Steady State 
 
RER at steady state decreased from baseline to midpoint (p<.05) and from baseline to 
endpoint (p<.01) in the LO treatment group.  RER did not change over time in the PLA or HI 
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treatment groups.  There were no significant overall time or treatment effects, nor was there a 
significant treatment by time interaction (Figure 12).  The change in RER was negatively 
correlated with the change in VO2MAX (r = -.326; p<.01), such as when VO2MAX increased, RER 
decreased. 
 
Time Trial Performance 
 
Time trial (TT) time to completion improved from baseline to endpoint for all treatment 
groups (PLA: p<.05, LO: p<.05, HI: p<.01).  TT time to completion improved from baseline to 
midpoint in LO (p<.01) and HI (p<.01) treatment groups.  Furthermore, TT time to completion 
improved from midpoint to endpoint (p<.01) in the HI treatment group.  The PLA group 
improved performance by 3.7%, the LO group improved performance by 2.4%, and the HI group 
improved performance by 4.7% from baseline to endpoint time trials.  There was a significant 
overall time effect (p<.01).  There was no significant overall treatment effect, nor was there a 
significant time by treatment interaction (Figure 13).  The TT time to completion was negatively 
correlated with lactate threshold (p<.01), such as when lactate threshold increased, TT time to 
completion decreased. 
TT blood lactate was greater at endpoint than at baseline (p<.01) in the HI treatment 
group.  There was no change in TT blood lactate over time in the PLA or LO treatment groups.  
There was a significant overall time effect (p<.05).  There was no significant overall treatment 
effect, nor was there a significant treatment by time interaction (Figure 14). 
TT RPE was greater at endpoint (p<.01) and midpoint (p<.01) than at baseline, and 
greater at endpoint than at midpoint (<.01) for the PLA treatment group.  Additionally, TT RPE 
was greater at endpoint than at midpoint (p<.05) for the PLA treatment group.  TT RPE did not 
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change over time in the LO or HI treatment groups.  There was a significant overall time effect 
(p<.01).  There was no significant overall treatment effect, nor was there a significant time by 
treatment interaction.  However, when the HI and LO HT treatment groups were combined and 
compared with PLA, there was a significant overall treatment effect (p<.05) with PLA higher 





The purpose of this study was to investigate if regular daily hydroxytyrosol (HT) 
supplementation for 6 weeks would increase mitochondrial biogenesis and improve endurance 
exercise performance in recreationally-active males compared with a placebo (PLA).  
Additionally, a low-dose supplement (LO, 50 mg/day HT) was compared with a high-dose 
supplement (HI, 150 mg/day HT) to determine whether there was a dose-response.  The primary 
findings were that HT supplementation increased oxidative enzymes SDH and CS, indicating 
activation of mitochondrial biogenesis.    Time trial performance was improved at midpoint and 
endpoint in the LO and HI HT treatment groups.  Improved time trial performance also occurred 
at endpoint in PLA, which was associated with an increased in RPE.  RPE was not associated 
with improved time trial performance when HT was provided. 
Adherence to a Mediterranean diet may improve longevity and reduce the risk for 
diseases associated with mitochondrial dysfunction and aging (Trichopoulou et al., 2003).  Olive 
oil is the primary source of fat in the Mediterranean diet (Quaranta and Rotundo, 2000).  Extra-
virgin olive oil is rich in antioxidant and radical-scavenging polyphenolic compounds, which are 
thought to be responsible for the relatively stable characteristics of olive oil (Visioli and 
Bernardini, 2011; Sabatini, 2010; Tuck et al., 2002).  Of these polyphenols, HT has been found 
in high concentrations in olive waste water, a by-product of olive oil manufacturing (Visioli et 
al., 1999).  Recently, the health benefits associated with the Mediterranean diet have been 
credited in part to the HT content of olive oil due to its potential to increase mitochondrial 
density and function in the cells (Granados et al. 2010; Paiva-Martins et al., 2011). Mitochondria 
are the cellular framework by which active tissues utilize delivered oxygen via oxidative 
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phosphorylation to produce ATP, the form of energy required for muscular work and 
maintenance of vital cellular processes.  Exercise and other conditions of high cellular oxidative 
demand (Vorobjev and Zorov, 1983; Nisoli and Carruba, 2006) induce mitochondrial biogenesis 
by activating AMPK (Hardie 2011) and the downstream mitochondrial transcription factor PGC-
1α (Irrcher et al, 2003; Lee et al., 2006). 
LO and HI HT caused increases in the oxidative enzymes SDH and CS, suggesting 
increased mitochondrial biogenesis.  This was originally noted in studies with polyphenols 
similar to HT in structure, such as quercetin, and resveratrol (Howitz et al., 2003; Lagouge et al., 
2006; Davis et al., 2009), and recent studies have found that HT at concentrations of 0.1 to 10 
µmol/L are able to likewise induce mitochondrial biogenesis and increase oxidative enzymes in 
isolated cells and in vivo in rodents (Hao et al., 2009; Zhu et al., 2010; Lui et al., 2011).  
Although the increase in SDH in the LO treatment group was not statistically significant, the 
percentage increase of 9.6% was similar to the increase of 9.4% in the HI HT group.  HT has 
been shown to activate AMPK (Hardie, 2011; Hao et al., 2009; Zhu et al., 2010; Lui et al., 2011), 
which regulates transcription of mitochondria by elevating the nuclear transcription factor 
peroxisome proliferator-activated receptor γ coactivator (PGC)-1α, a master regulator of 
mitochondrial biogenesis (Irrcher et al., 2003; Lee et al., 2006).  However, the increase in 
oxidative enzymes in the HT groups was not associated with an increase in PGC-1α.  Since the 
increase in mitochondrial oxidative enzymes was modest, it is possible that an increase in PGC-
1α by HT was too small to detect. 
 Maximal aerobic power, VO2MAX, was unaffected by HT.  Although VO2MAX was 
statistically higher in the LO HT group, such a small increase would not be expected to have 
physiologically relevant implications.  HT should probably have little influence on VO2MAX, 
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considering that whole-organism VO2MAX is limited by oxygen delivery rather than by 
mitochondrial volume.  In fact, DiPrampero (1985) demonstrated that approximately 75% of 
VO2MAX is determined by oxygen delivery, and the remaining 25% is determined by peripheral 
factors including mitochondrial volume.  However, the VO2 at which blood lactate begins to 
increase, lactate threshold, is highly related to mitochondrial density (Ivy et al., 1980).   
Lactate is a product of anaerobic metabolism, which provides a rapid source of ATP via 
glycolysis in the cytosol of the cell.  During high intensity exercise, the rate of lactic acid 
production eventually overwhelms the blood bicarbonate buffering system, leading to lactate 
accumulation and fatigue (Harrison and Pilcher, 1930; Holloszy et al., 1977).  Increased 
mitochondria allow distribution of the oxidative demand, allowing an individual to rely primarily 
on aerobic metabolism at higher exercise intensities before anaerobic metabolism becomes the 
primary energy source (Holloszy and Coyle, 1984).  In this regard, it was observed that lactate 
threshold increased in the LO HT group.  In addition, RER was significantly lower at steady state 
exercise and time trial performance significantly improved for the LO HT group, indicating a 
shift of reliance from anaerobic to aerobic metabolism at a given exercise intensity (Hill et al., 
1924; Harrison and Pilcher, 1930; Wasserman and McIlroy, 1964).  This provides further 
evidence that there was an increase in mitochondria in the HT groups. 
Although the HI HT group demonstrated increased SDH and CS, this increase was not 
accompanied by an increased lactate threshold or RER.  It is possible that a type II error 
occurred, such as a treatment effect existed for lactate threshold that went undetected due to 
sampling error.  The HI HT group entered the study with a higher mean lactate threshold and a 
lower RER at steady state than did the LO HT group.  Perhaps the LO group experienced an 
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exaggerated response to HT supplementation because it was less trained and may have had lower 
intrinsic antioxidant capacity than the HI HT group (McArdle, 2000). 
Time trial performance increased in each group over the course of the study, indicating a 
familiarization effect independent from the treatment.  Performance improved at midpoint testing 
and at final testing in the HT groups, whereas performance in the PLA group did not improve 
until the final time trial.  The increase in performance in the HT groups was accompanied by an 
increase in mitochondrial activity.  PLA had no increase in mitochondrial activity.  However, the 
increased performance in the PLA group was accompanied by a significant increase in RPE, 
whereas the LO and HI HT treatment groups did not demonstrate increased RPE.  Collectively, 
these observations suggest that HT may have altered perception of effort during the time trial.  
No previous study has reported altered RPE during exercise in response to HT supplementation, 
although Alexander (2006) found that quercetin acts as an adenosine A1 receptor antagonist in 
vitro, similarly to caffeine.  HT may act similarly to other phenols such as caffeine and quercetin 
to limit CNS perception of effort during exercise.  This theory is in agreement with Davis et al. 
(2009), who attributed increased voluntary running in mice after quercetin supplementation to 
decreased CNS perception of effort. 
The improvement in time trial performance in the LO HT group was accompanied by an 
increased lactate threshold and a decreased RER, in addition to improved mitochondrial enzyme 
activity.  However, LT and RER were unchanged in the HI HT group.  Therefore, improvement 
in time trial performance may have involved factors other than cellular adaptations.  When 
considering our results, psychological motivation should be taken into account.  Each subject 
was able to view and compete with his fastest previous time trial performance.  Average time to 
complete the time trial and the fastest time to completion across all subjects was also posted in 
28 
 
the laboratory as another means of externally motivating the subjects to perform the time trial at 
maximum exercise capacity.  Lactate threshold has been found to be the primary determinant of 
endurance exercise performance in athletes since endurance racers typically perform at an 
intensity equal to lactate threshold, but below VO2MAX (Allen et al., 1985).  However, it appears 
that the psychological motivation of the subjects to beat previous performances was a stronger 
predictor of performance than was lactate threshold or RER.  This is suggested by the 
performance of the PLA group, in which an increase in performance was accompanied by an 
increase in RPE.  It is possible that a treatment effect may have been more pronounced if the 
subjects had not been provided with external psychological motivation, or if the study was 
examining a population typically accustomed to maintaining a race intensity equal to lactate 
threshold, such as competitive cyclists. 
Our results indicate that 50 mg/day of HT, equivalent to 0.6 mg/kg body weight/day, for 
6 weeks is as efficacious as 150 mg/day, equivalent to 1.9 mg/kg body weight/day, for improving 
muscle oxidative capacity and aerobic performance.  This finding is supported by earlier research 
in rats which showed that 0.5 mg/kg/day of HT for 6 weeks improved mitochondrial function 
(Granados et al., 2010). 
In summary, the present study demonstrated that HT supplementation for 6 weeks in 
recreationally-active males increased the activity of muscle oxidative enzymes, suggesting an 
increase in mitochondrial biogenesis.  Time trial performance increased in the HT groups over 
the course of the study and was accompanied by an increase in LT in the LO HT group.  Despite 
no increase in mitochondrial enzyme activity or LT, performance was improved after 6 weeks in 
the PLA group.  This improvement was associated with an increase in RPE.  RPE was not 
increased in either the LO or HI groups, although time trial performance was significantly 
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improved.  It is possible that HT can improve performance by altering perception of effort, as 
well as by improving muscle oxidative capacity. 
The present study is the first to show that HT is able to stimulate mitochondrial 
biogenesis, increase aerobic capacity, and decrease perception of effort in humans.  These 
findings are highly relevant to endurance athletes and to individuals suffering from diseases 
related to mitochondrial dysfunction, such as cardiovascular disease, type II diabetes, and cancer.  
Olive oil waste water, which is rich in HT, may be transformed from a logistically and 
financially burdensome by-product of olive oil production into a valuable commodity.  HT 
isolated from this waste water may be used as an effective means to increase mitochondria and 
gain benefits such as improved exercise performance, slowed aging, and decreased diseases 
associated with mitochondrial dysfunction. 
Future research should strive to identify the specific mechanisms by which HT decreases 
perception of effort in humans.  Additionally, acute effects of HT should be compared with 
chronic effects of HT, and the smallest efficacious acute dose of HT should be determined.  
Moreover, the effects of HT supplementation on endurance exercise performance should be 
examined in endurance athletes to determine if HT can increase oxidative enzymes, improve 
lactate threshold and RER, and decrease perceived effort in a trained population, and to 
determine whether any improvements translate into improved endurance exercise performance.  
Further research should be also pursued in a clinical population to determine whether HT is 
capable of decreasing diseases associated with mitochondrial dysfunction and aging such as 
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TABLE 1:  Subject characteristics, M ± SE 
  All PLA LO HI 
  (N=60) (n=19) (n=20) (n=22) 
Age (yrs) 21.46 ± 0.22 21.68 ± 0.43 21.60 ± 0.41 21.14 ± 0.31 
Height (cm) 179.46 ± 0.79 180.02 ± 1.07 181.57 ± 1.26 177.08 ± 1.52 
Weight (kg) 78.91 ± 1.19 80.40 ± 2.29 79.48 ± 2.04 77.11 ± 1.93 
BMI 24.46 ± 0.32 24.78 ± 0.64 24.08 ± 0.57 24.54 ± 0.47 
VO2MAX (L O2•min
-1
) 3.39 ± 0.07 3.56 ± 0.14 3.24 ± 0.10 3.38 ± 0.13 
Lactate Threshold  (L O2•min
-1
) 1.97 ± 0.09 2.07 ± 0.11 1.77 ± 0.08 2.07 ± 0.09 




FIGURE 1:  Molecular structure of hydroxytyrosol 
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LT/VO2MAX LT/VO2MAX LT/VO2MAX
SS/TT SS/TT SS/TT
LT/VO2MAX:  Lactate threshold test with a concurrent VO2MAX test was performed on a bicycle ergometer (2 min stages progessing by 20 or 30 watts until VO2MAX was achieved)
          Measurements:   Lactate threshold (watts), lactate threshold (% of VO2MAX), VO2MAX (watts), VO2MAX (O2 L•min
-1
)
SS/TT:  Steady state ride was performed on a bicycle ergometer (20 min at 65% VO2MAX) followed by a time trial ride (20 km course) on a bicycle ergometer
         Measurements:   Steady state RER at 65% VO2MAX, time trial average watts, time to complete time trial
Familiarization
Hepatitis B/C screen
Muscle Biopsy Muscle Biopsy
Description of Visits
Muscle Biopsy:  Aprroximately 100 mg of muscle tissue was removed from participant's thigh region and protein contect was analyzed
           Measurements:   PGC-1α, SDH, CS
Blood Safety:  Blood sample was drawn and analyzed to ensure the study supplement was safe for consumption
          Measurements:   Lipid panel, blood cell panel, metabolic panel, lipase, amylase, hemoglobin A1c, GGT, uric acid, LDH, total CK, phosphorus
Day of Supplementation:
Day of Study:






FIGURE 2:  Study protocol 
36 
 


































50% VO 2MAX  (warm-up)
  














FIGURE 6: Succinate dehydrogenase (SDH).  SDH changes within treatments over time were 
analyzed in tissue collected from muscle biopsies at baseline and endpoint.  Values are presented 
as M ± SE.  No significant overall treatment by time interaction.  * Significant difference 






FIGURE 7: Citrate synthase (CS).  CS changes within treatments over time were analyzed in 
tissue collected from muscle biopsies at baseline and endpoint.  Values are presented as M ± SE.  
No significant overall treatment by time interaction.  * Significant differences between baseline 





FIGURE 8: PGC-1α.  PGC-1α changes within treatments over time were analyzed in tissue 
collected from muscle biopsies at baseline and endpoint.  Values are presented as M ± SE.  No 





FIGURE 9: α-tubulin.  α-tubulin changes within treatments over time were analyzed in tissue 
collected from muscle biopsies at baseline and endpoint.  Values are presented as M ± SE.  No 





FIGURE 10: VO2MAX.  VO2MAX changes within treatments over time.  VO2MAX was measured 
by a graded exercise test on a bicycle ergometer at baseline, midpoint, and endpoint.  Values are 
presented as M ± SE.  No significant overall treatment by time interaction.  * Significant 
differences between baseline and endpoint (p<.01) and between midpoint and endpoint (p<.05) 





FIGURE 11: VO2 at Lactate Threshold.  Changes in VO2 at lactate threshold within treatments 
over time.  VO2 at lactate threshold was measured by a graded exercise test on a bicycle 
ergometer at baseline, midpoint, and endpoint.  Values are presented as M ± SE.  Significant 
overall treatment by time interaction (p<.01).  * Significant differences between baseline and 






FIGURE 12: Respiratory exchange ratio (RER) at Steady State.  Changes in RER at steady 
state within treatments over time.  RER at steady state was measured during an exercise test at 
constant watts equivalent to 65% VO2MAX on a bicycle ergometer at baseline, midpoint, and 
endpoint.  Values are presented as M ± SE.  No significant overall treatment by time interaction.  
* Significant differences between baseline and midpoint (p<.05) and between baseline and 





FIGURE 13: Time Trial (TT) time to completion.  TT time to completion within treatments 
over time.  TT time to completion was measured as time to complete a 20 km time trial course on 
a bicycle ergometer at baseline, midpoint, and endpoint.  Values are presented as M ± SE.  No 
significant overall treatment by time interaction.  *Significant differences between baseline and 
endpoint (p<.05) and between midpoint and endpoint in the PLA treatment group (p<.05).  
*Significant differences between baseline and midpoint (p<.01) and between baseline and 
endpoint (p<.05) in the LO treatment groups.  * Significant differences between baseline and 
midpoint (p<.01) and between baseline and endpoint (p<.01) in the HI treatment group.  † 
Significant difference between midpoint and endpoint (p<.01) in the HI treatment group. 
* 





FIGURE 14: Time Trial (TT) blood lactate.  TT blood lactate within treatments over time.  TT 
blood lactate was measured in the final blood draw of baseline, midpoint, and endpoint time 
trials.  Values are presented as M ± SE.  No significant overall treatment by time interaction.  





FIGURE 15: Time Trial (TT) ratings of perceived exertion (RPE).  TT RPE within 
treatments over time.  TT RPE was collected as the final blood draw of baseline, midpoint, and 
endpoint time trials.  No significant overall treatment by time interaction.  * Significant 
differences between baseline and midpoint (p<.05) and between baseline and endpoint (p<.01) in 
the PLA treatment group.  † Significant difference between midpoint and endpoint (p<.01) in the 












Adherence to a Mediterranean diet may improve longevity and reduce the risk for 
diseases associated with mitochondrial dysfunction and aging, such as cardiovascular disease, 
type II diabetes, and cancer.  A population-based investigation of 22,043 adults in Greece for a 
period of 44 months established inverse correlations with adherence to the traditional 
Mediterranean diet and total mortality, deaths due to coronary heart disease, and deaths due to 
cancer (Trichopoulou et al., 2003).   
The traditional Mediterranean diet is characterized by high intake of fresh fruits and 
vegetables, fish, cheese, wine in moderation, low levels of red meat consumption, and olive oil 
as the predominant source of fat (Willett et al., 1995).   Olive oil contributes to 71, 42, and 37% 
of the amount of vegetable fat obtained in the diet in Greece, Italy, and Spain, respectively 
(Quaranta and Rotundo, 2000).  Olive trees possess over 30 potent antioxidant and radical-
scavenging polyphenolic compounds that are protective against harsh heat and sun exposure of 
the Mediterranean basin (Visioli et al., 1998).   Extra virgin olive oil is unique from other types 
of vegetable oils because it is rich in these phenolic compounds, which are thought to be 
responsible for the comparatively stable characteristics of olive oil (Visioli and Bernardini, 2011; 
Sabatini, 2010; Tuck et al., 2002).   
The simple phenolic structure is characterized by a carbon aromatic ring linked to a 
hydroxyl group (Bravo, 1998).  Hydroxytyrosol (3,4-dihydroxyphenyl ethanol) (HT) is a type of 
polyphenol which consists of a carbon aromatic ring linked to 2 hydroxyl groups and an ethanol 
group (Quiles et al., 2002).  Recently, the health benefits associated with the Mediterranean diet 
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have been credited to the HT content of olive oil due to its potential to increase mitochondrial 
density and function in cells (Granados et al., 2010; Paiva-Martins et al., 2011).  HT and its 
derivatives comprise approximately 50% of the phenolic compounds found in extra virgin olive 
oil (Raederstorff, 2009).  Olive oil waste water, which is a product of olive oil manufacturing, is 
rich in HT.  Currently, disposal of olive waste water represents a significant burden to olive oil 
manufactures, but if HT is found to evoke significant health benefits, this waste water may be a 
valuable commodity (Visioli et al., 1999).   
 
Role of Mitochondria in Energy Production and Exercise Performance 
 
Mitochondrial Metabolism 
Mitochondria, located in the cytosol of most eukaryotic cells, are the cellular framework 
by which active tissues utilize delivered oxygen via oxidative phosphorylation.  Mitochondria 
require the presence of oxygen to break down nutrients to produce adenosine triphosphate 
(ATP), the form of energy required for muscular work and maintenance of processes necessary 
for the cell to survive (Lardy and Ferguson, 1967).  Acetyl CoA derived from the breakdown of 
fatty acids or carbohydrates enters the citric acid cycle (also known as the Krebs cycle) in the 
mitochondrial matrix and becomes a source of hydrogen to convert coenzymes nicotinamide 
adenine dinucleotide (NAD+) and flavin adenine dinucleotide (FAD) to reduced states NADH 
and to FADH2, respectively.  Hydrogens carried by NADH and FADH2 are oxidized and the 
extracted electrons are passed along the respiratory chain of the mitochondria (Alberts, 2008). 
The respiratory chain of the mitochondria consists of a series of cofactors, most of which 
are cytochromes (iron-protein electron carriers), that are grouped into five large respiratory 
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enzyme complexes.  Hydrogens are donated from NADH + H
+
 to complex I (NADH 
dehydrogenase) or from FADH2 to complex II (succinate dehydrogenase (SDH)).  These 
hydrogens are quickly split by the reduced coenzymes into protons (H
+
) plus electrons.  H
+
 is 
pumped into the intermembrane space by the enzyme complexes while electrons continue to be 
transferred along the chain to complex III (cytochrome c reductase).  Cytochrome c, a protein 
loosely associated with the mitochondrial membrane, transfers electrons from complex III to 
complex IV (cytochrome c oxidase), and finally the electrons are accepted by ½ O2 to form H2O 
as a by-product.  Complex V of the respiratory chain is the inner membrane-associated enzyme 
complex ATP synthase, which harnesses the electrochemical gradient created by the proton 
pumps to drive the synthesis of ATP from mitochondrial matrix-associated ADP and an 
inorganic phosphate ion (Alberts 2008).  The coupling of ATP to cellular proteins allows 
energetically-unfavorable reactions such as muscle contraction to occur. 
 
Maximal Oxygen Consumption 
 
A VO2MAX test measures an individual‘s expired gases during a graded exercise test 
involving aerobic exercise such as running or cycling.  As exercise intensity increases, the 
oxygen demand of the mitochondria increases; therefore, oxygen consumption increases 
proportionally to increasing workload (Barstow et al., 1993).  Eventually, the maximal rate of 
aerobic metabolism no longer adequately matches oxygen demand, and VO2MAX  is reached 
when oxygen consumption does not increase despite an increase in workload.    VO2MAX is 
negatively associated with all-cause mortality (Blair et al., 1989) and is a major factor governing 





Another main, and arguably the most important, determinant of endurance exercise 
performance is lactate threshold since endurance races are typically performed at an intensity 
equal to lactate threshold, but below VO2MAX (Allen et al., 1985).  Lactate threshold, which can 
be measured via blood sampling during a graded exercise test, is the point of lactate 
accumulation in the blood above baseline levels (Ivy et al., 1980). 
Lactate is a product of anaerobic metabolism, which provides a rapid source of ATP via 
glycolysis in the cytosol of the cell.  Stored muscle glycogen enters glycolysis and is eventually 
converted to pyruvate.  Pyruvate can then be shuttled into the mitochondria, where it is converted 
to acetyl CoA and then enters the citric acid cycle and oxidative phosphorylation.  However, 
during high intensity exercise, pyruvate cannot be shuttled into the mitochondria in proportion to 
the rate it is produced (Holloszy et al., 1977).  Instead it is converted to lactic acid in the cytosol 
and then diffuses into the blood.  The blood contains a bicarbonate buffering system that 
converts lactic acid into lactate and carbon dioxide (Harrison and Pilcher, 1930). 
As the body continues to increase its reliance on anaerobic metabolism, lactic acid 
production from glycolysis begins to overwhelm the blood buffering system, and lactate 
accumulates in the blood and working skeletal muscle.  Lactate accumulation eventually results 
in decreased blood and skeletal muscle pH, leading to fatigue and forcing the individual to 
decrease exercise intensity.  Decreased skeletal muscle pH directly inhibits certain aerobic 




Endurance Training Adaptations 
 
Endurance training increases lactate threshold, allowing an individual to exercise at a 
higher intensity before experiencing lactate accumulation and fatigue (Allen et al., 1985).  
Typically, lactate threshold occurs at approximately 60% of VO2MAX in untrained individuals, 
whereas in trained individuals, lactate threshold can occur at much higher exercise intensities—
75 to 90% of VO2MAX (Joyner and Coyle, 2008).  Ivy et al., (1980) observed that lactate 
production is primarily influenced by the oxidative capacity of the muscle.  Major training 
adaptations that are responsible for this relative shift in lactate threshold include increased 
mitochondrial density and function within the skeletal muscle (Henriksson, 1977).  The shift 
from primarily anaerobic to aerobic metabolism at a given exercise intensity is accompanied by a 
shift in substrate utilization from primarily carbohydrates to fats, which can be measured by 
Respiratory Exchange Ratio (Hill et al., 1924; Harrison and Pilcher, 1930; Wasserman and 
McIlroy 1964).  Increased mitochondria allow distribution of the oxidative demand, allowing an 
individual to rely primarily on aerobic metabolism at higher exercise intensities before anaerobic 




Mitochondrial biogenesis is the term commonly used to describe the formation of new 
mitochondria through activation of specific transcription factors and signaling pathways inside 
the cell (Attardi and Schatz, 1988).  Exercise and other conditions of high cellular oxidative 
demand (Vorobjev and Zorov, 1983; Nisoli and Carruba, 2006) induce mitochondrial biogenesis 
by activating 5‘-AMP activated protein kinase (AMPK) in the cytosol of the cell (Brunk, 1981; 
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Moyes et al., 1997; Little et al., 2011).  AMPK acts as a cellular energy sensor; it is activated by 
an increased cellular AMP:ATP ratio, which occurs at the onset of exercise or under conditions 
of low nutritional availability (Hardie, 2011).  
AMP activates AMPK by binding to its regulatory subunit, which causes phosphorylation 
of the catalytic subunit by upstream kinases.  Upon activation, AMPK switches on catabolic 
pathways that generate ATP such as glycolysis, fatty acid oxidation, and mitochondrial 
biogenesis; congruently it switches off anabolic pathways that consume ATP such as lipogenesis 
(Hardie, 2011).  AMPK regulates transcription of mitochondria by elevating nuclear 
transcription factor peroxisome proliferator-activated receptor γ coactivator (PGC)-1α, a master 
regulator of mitochondrial biogenesis (Irrcher et al., 2003; Lee et al., 2006).  PGC-1α expression 
is directly regulated by relative exercise intensity (Egan et al., 2010; Nordsborg et al., 2010).  
Furthermore, upregulation of PGC-1α coincides with increased mRNA expression of 
mitochondrial genes (Viollet et al., 2007; Little et al., 2011). 
 
HT Promotes Mitochondrial Biogenesis and Function 
 
Background Polyphenol Research 
 
Nearly a decade ago, researchers began to examine the ability of polyphenols to induce 
mitochondrial biogenesis and enhance mitochondrial function.  Resveratrol, a polyphenol found 
in the skin of grapes, originally gained notoriety for its ability to activate the silent information 
regulator two (Sir2) pathway, which is credited for lifespan extension during caloric restriction in 
various species (Howitz et al., 2003; Rogina and Helfand, 2004).  Baur et al. (2006) 
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demonstrated that long-term resveratrol supplementation did indeed extend the lifespan of mice.  
Howitz et al., (2003) found that resveratrol increased the mammalian Sir2 homolog (SIRT1), an 
upstream activator of PGC-1α, in mouse skeletal muscle.  Similarly, Lagouge et al. (2006) found 
that resveratrol treatment increased SDH, CS, and SIRT1 in mouse skeletal muscle.   
Based on these findings, Davis and colleagues (2009) examined the effects of quercitin, a 
similar polyphenol derived from a wide variety of food plants including red onions, apples, and 
berries, on mitochondrial biogenesis and endurance exercise performance in mice.  Mice were 
administered 12.5 or 25 mg/kg of quercitin supplement for 7 days.  After 7 days, the mice were 
exercise tested, then killed and the soleus muscle and brain were analyzed for mRNA expression 
of PGC-1α.  Quercitin increased brain and skeletal muscle mRNA expression of PGC-1α, 
accompanied by increased maximal endurance capacity and voluntary wheel running activity.  
Quiles attributed increased voluntary wheel running activity to decreased perception of effort.  
Alexander (2006) showed that phenols such as querctin act as adenosine A1 receptor antagonists 
in vitro, similarly to caffeine.  Additionally, quercetin supplementation was found by MacRae 
and Mefferd (2006) to improve 30 km cycling time trial performance by 3.1% in elite male 
cyclists.  There was no increase in VO2MAX observed in this study.  Instead, the increase in 
performance was attributed to increased relative power output over the time trial course. 
 
Hydroxytyrosol Promotes Mitochondrial Biogenesis 
Because of its structural similarity other members of the polyphenolic family such as 
quercitin and resveratrol, researchers have recently examined the ability of HT to likewise 
increase mitochondrial biogenesis and enhance endurance exercise performance.   
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Hao et al. (2009) demonstrated for the first time that HT is capable of stimulating 
mitochondrial biogenesis via activation of PGC-1α in isolated rodent 3T3-L1 adipocytes.  Cell 
cultures and differentiation of 3T3-L1 cells are commonly used as models of adipogenic 
differentiation and insulin resistance because they are sensitive to insulin, and display insulin-
sensitive glucose uptake similarly to primary adipose cells.  Cultured cells were incubated with 
HT at concentrations of 0.1, 1, 10, and 50 µmol/L for 24 hours.  Treatment of cells with HT at 
0.1-50 µmol/L resulted in dose-dependent stimulation of PGC-1α.  HT treatment at a 
concentration of 1 µmol/L resulted in a significant increase in mtDNA.  HT treatment at 
concentrations of 0.1, 1, and 10 µmol/L increased the expression of mitochondrial complexes I 
and II, while HT concentrations of 1 and 10 µmol/L increased expression of complexes III and 
IV.  These increases in mitochondrial complex protein expression were approximately 1.5- to 
1.7-fold compared to control samples.  Consequently, mitochondria density increased and 
mitochondrial function was enhanced, indicated by increased activity of mitochondrial 
complexes I through IV, increased oxygen consumption, and decreased free fatty acid content of 
the cell.  These findings were confirmed by Zhu et al. (2010), who likewise demonstrated that 
HT was capable of inducing mitochondrial biogenesis in vitro via activation of PGC-1α in 
isolated human ARPE-19 human retinal pigment epithelial cells. 
To further examine the effects of HT on mitochondrial function and endurance exercise 
performance, Liu et al., (2011) supplemented mice with 50, 150, or 300 mg/kg body weight HT 
once per day for 3 weeks.  After 3 weeks of treatment, maximal running distance on a treadmill 
was measured.   HT increased the running distance to exhaustion in all treatment groups 
compared to placebo.  The treatment group which was administered 300 mg/kg body weight HT 
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per day significantly increased run time to exhaustion compared to the 50 and 150 mg/kg body 
weight HT treatment groups. 
In an unprecedented HT supplementation study in humans (Rietjens et al., 2011), eight 
healthy males (22.0 ± 1.9 years of age, 75.4 ± 3.3 kg, 1.8 ± 0.02 m, 22.7 ± 0.8 BMI) with no 
history of participation in a regular exercise program were given an olive oil supplement and 
exercise-induced lactate accumulation was evaluated.  The subjects were instructed to avoid 
consumption of olives, olive oil, olive products, and other specific foods which contain high 
levels of antioxidants or polyphenols during the three days prior to and on the day of 
experimental testing, and to refrain from strenuous exercise during the study period.  In a cross-
over design, subjects were tested once after consumption of a supplement beverage containing 
200 mg of HT, and once after consumption of a placebo.  The supplement was consumed once at 
8:00 PM on the night prior to experimental testing, and again 30 min prior the start of exercise 
testing.  After a 5-min warm-up on a Stairmaster, subjects performed 8 sets of 10 repetitions on a 
horizontal leg press machine, followed by 8 sets of 10 repetitions on a leg extension machine.  
Both exercises were performed at 75% of the subject‘s individual 1 repetition maximum (RM) 
with 2-min rest intervals between sets.  Blood samples were collected before the start of the 
exercise, during the exercise, and up to 2.5 hr after exercise.  Analysis of plasma lactate 
concentrations indicated that plasma lactate considerably increased during exercise, but HT 
treatment attenuated the increase in plasma lactate (12.8-fold increase above baseline) compared 
to placebo (14.8-fold increase above baseline). Blood lactate was expressed as percent of 
baseline, however actual blood lactate values were not reported in this study.  Although this 
attenuation of lactate was statistically significant, the physiological relevance is questionable. 
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  In order to observe the protective effects of HT on exercise-induced cellular damage, 
Feng and colleagues (2011) strenuously exercised rats to induce cellular damage.  While physical 
exercise is beneficial to health, excessive exercise can lead to chronic fatigue, muscle damage, 
and impaired immune function (Shephard 1994; Smith 2003).  Rats which were treated with 25 
mg/kg/day HT displayed enhanced endurance capacity and decreased immune system damage.  
HT treatment protected against inhibition of PGC-1α and enhanced mitochondrial complex I and 
II activities. 
 
Hydroxytyrosol is an Antioxidant 
 
Increased mitochondrial function may improve mitochondrial function by decreasing 
mitochondrial production of reactive oxygen species (ROS).  The electron transport chain of the 
mitochondria is highly efficient, but electron leakage does occur in proportion to the rate of 
mitochondrial respiration, resulting in generation of ROS.  ROS are oxygen radicals consisting 
primarily of superoxide anions (O2
• -
), hydrogen peroxide (H2O2), and hydroxyl radicals (
• 
OH); 
these radicals are capable of damaging cellular deoxyribonucleic acid (DNA), lipids, and other 
molecules (Wallace, 2005).  A low level of ROS production is necessary to control important 
cellular functions, but a high level of ROS production can cause mutations of the mitochondrial 
DNA (mtDNA) (Chan, 2006).  Most mitochondrial proteins are encoded by the nuclear genome 
and imported into the mitochondria, but the mitochondria retains some DNA that is essential for 
its respiratory function (Wallace, 2005).   
It has been proposed that mtDNA mutations decrease the efficiency of the electron 
transport chain, thus decreasing ATP production and further increasing production of ROS 
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(Richter, 1988; Zhang et al., 1990).  This cycle of mtDNA mutation and disrupted respiratory 
function provides the basis for the theory that mitochondrial dysfunction plays a critical role in 
the aging process (Richter, 1995) and the development of degenerative diseases (Harman, 1956, 
1992; Linnane et al., 1989; Lowell and Shulman, 2005; Murrow and Hoehn, 2010).  Tissues 
which are highly dependent on cellular respiration such as brain, skeletal muscle, cardiac muscle, 
and endocrine are thought to be particularly susceptible to mitochondria-associated diseases 
(Wallace, 1999).  High levels of ROS and oxidative damage to mtDNA have been consistently 
observed in age-associated diseases (Melov et al., 1999; Cooke et al., 2003; Pelicano et al., 2004; 
Zmijewski et al., 2005; Matthews, 2006).  In fact, Barja and Herrero (2000) found that oxidative 
damage to mitochondria in the heart and brain of mammals was inversely related to maximum 
lifespan.  Additionally, Nieman et al. (2003) found an association between ROS and fatigue in 
ultramarathon subjects. 
Liu and colleagues (2007) examined the protective effects of HT on acrolein-induced 
toxicity in the human retinal pigment epithelial cell line ARPE-19, a cellular model of smoking- 
and age-related macular degeneration.  Acrolein is an oxidant found in cigarette smoke, and is 
also a product of lipid oxidation in vivo.  Treatment of cells with 75 µmol/L of acrolein for 24 
hours induced mitochondrial dysfunction and increased ROS, indicated by decreased 
mitochondrial membrane potential, depressed activities of mitochondrial complexes, reduced 
number of viable mitochondria, decreased oxygen consumption, reduced factors for 
mitochondrial biogenesis, and increased intracellular calcium.  Pre-treatment of the ARPE-19 
cells with HT protected against ROS-induced damage and mitochondrial dysfunction.  In a dose- 
and time-dependent manner, pre-treatment of cells with greater than 75 µmol/L of HT for 24 
hours effectively protected cells, while 5 µmol/L of HT for 7 days showed a similar protective 
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effect.  Thus, researchers concluded that HT supplementation may function as an effective 
therapeutic treatment of smoke-induced or age-related macular degeneration of human retinal 
pigment epithelial cells.  This conclusion supports the findings of an earlier study by Quiles et al. 
(2002), which demonstrated that treatment of human prostate cells with HT for 24 hours at 
concentrations as low as 10 μM decreased ROS production and reduced ROS-induced mtDNA 
damage. 
 
Hydroxytyrosol Improves Mitochondrial Control of the Cell Cycle 
 
 Not only can ROS damage mitochondrial enzymes necessary for oxidative 
phosphorylation, but high levels of ROS may also inhibit the mitochondria‘s control over the cell 
cycle (Brandon et al., 2006). In a properly-functioning cell, intracellular mechanisms which 
signal apoptosis are activated in response to cellular damage and dysfunction.  High levels of 
ROS may oxidize certain pro-apoptotic intracellular proteins such as p53, inhibiting apoptosis 
and allowing survival and proliferation of malignant cells, possibly progressing to cancer 
(Hussain et al., 2003; Halliwell, 2007).  It has been observed that animals with impaired ability 
to scavenge ROS have increased risk for developing cancers later in life (Halliwell, 1984; Kim et 
al., 2001; Sutton, 2003). 
A novel study by Granados and colleagues (2011) demonstrated for the first time in 
animals that HT inhibits growth and cell proliferation of mammary tumors.  The growth of these 
tumors in rats was induced by dimethylbenz[α]anthracene.  The treatment group was 
administered 0.5 mg/kg body weight HT 5 days per week for 6 weeks.  HT treatment altered 
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expression of genes related to apoptosis, cell cycle, proliferation, differentiation, survival and 
transformation pathways.  These findings are in agreement with research by Notarnicola et al. 
(2011), which tested the effects of HT in two independent human colon cancer cell lines, HT-29 
and SW620.  HT had an anti-proliferative effect and was able to induce apoptosis in both cell 
lines.  Bouallagui et al. (2010) showed similar results in MCF-7 human breast cancer cells. 
 
Bioavailability and Safety of Hydroxytyrosol 
 
A growing body of literature has made a valid case for the potential use of HT as a 
nutritional supplement to improve exercise tolerance and to treat mitochondria-associated 
diseases, though there has recently been disagreement in the literature involving the 
bioavailability of HT upon ingestion and its potential biological antioxidant activity in humans.   
Because HT is a polar compound, it is likely to be excreted by the kidneys into the urine 
either in its unconjugate or conjugate form.  Visioli and colleagues (2000) observed that after 
ingestion of 50 ml of an olive oil sample, the conjugate form of HT was increased in the urine in 
direct proportion to the amount of olive oil ingested, indicating that HT was dose-dependently 
absorbed in humans.  To confirm this observation, Pinto et al. (2006) perfused cells of the 
jejunum and ileum of the small intestine with phenolic compounds including HT.  They found 
that HT was indeed absorbed and metabolized by the cells of the small intestine, indicated by the 
presence of HT in its conjugate form. 
In contrast, Vissers et al. (2004) reviewed available literature related to the bioavailability 
of olive oil phenols in animal and human studies.  His group concluded that, of the studies 
reviewed, animals which were treated with olive oil that had high phenol content consistently 
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demonstrated improved markers of oxidation, but 5 out of 7 studies in humans did not 
demonstrate equivalent beneficial effects.  Furthermore, Vissers suggested that 50 g of olive oil 
per day provides approximately 2 mg of HT equivalents per day.  This amount of HT results in a 
blood concentration of 0.06 µmol/L; an amount lower than the minimum concentrations required 
to illicit antioxidant activity in vitro.  Similarly, Khymenets et al. (2010) supplemented 
individuals with 50 mg of virgin olive oil and did not find significant antioxidant activity at the 
observed concentrations (0.01-10 µM). 
According to preliminary safety testing (Edwards et al., 2009), HT is rapidly absorbed 
after oral intake, and is rapidly and widely spread throughout rat tissues, with no indication of 
accumulation in the tissues.  The No Observed Adverse Effect Level (NOAEL) of HT 
supplementation in a 4-week trial in rats was a dosage of 560 mg/kg of body weight/day.  In a 
13-week clinical trial, the NOAEL of HT was 252 mg/kg body weight/day.  HT dosage at 200 
mg/day resulted in decreased sperm velocity in males.  This condition was fully reversed upon 
the removal of the HT supplement, and did not result in any permanent dysfunction of sex organs 
or impairment of sperm development.  Accordingly, the acceptable daily intake (ADI) of HT for 
males should be 150 mg/day.  In an embryo toxicity study, the NOAEL of HT was 168 mg/kg 
body weight/day.  An HT dosage of 504 mg/kg body weight/day resulted in a slight reduction of 
maternal and fetal bodyweight.  Accordingly, the ADI of HT for females should be 100 mg/day.  
Furthermore, an Ames test confirmed that HT has no mutagenic potential (Edwards et al., 2009). 
Collectively, these data indicate that HT is biologically available to humans upon 
ingestion and is generally non-toxic; however it is debated whether the amount of HT required to 





Adherence to a Mediterranean diet may improve longevity and reduce the risk for 
diseases associated with mitochondrial dysfunction and aging, such as cardiovascular disease, 
type II diabetes, and cancer.  It appears that HT, a polyphenolic component of extra virgin olive 
oil, is responsible for these health benefits.  HT may exert its beneficial effects by increasing 
mitochondrial biogenesis and function inside the cell.  VO2MAX and lactate threshold, both 
factors which dictate endurance exercise performance, are highly influenced by skeletal muscle 
mitochondrial volume and function.  The rate of oxidative phosphorylation in the mitochondria is 
a major limiter of exercise performance.  Increased mitochondria enhance exercise performance 
by decreasing reliance on glycolysis and increasing reliance on oxidative phosphorylation at a 
given exercise intensity.  HT stimulates mitochondrial biogenesis through the activation of 
AMPK and downstream transcription factor PGC-1α.  Dysfunctional mitochondria have been 
associated with decreased exercise tolerance, as well as age-associated diseases including type II 
diabetes, atherosclerosis, and cancer.  A common theory for mitochondrial-based disease is the 
mutation of mtDNA by ROS.  ROS are by-products of oxidative phosphorylation, but damage to 
the mitochondrial respiratory enzymes can increase ROS production, resulting in oxidation of 
mtDNA, which further compounds ROS production.  HT protects isolated cell lines from ROS 
production and oxidation and enhances mitochondrial control of the cell cycle in isolated cell and 
animal models.  The beneficial effects of HT have been clearly demonstrated in vitro and in 
animal models, but there is no research to-date showing HT-induced mitochondrial biogenesis in 
humans.  Most investigators agree that HT is biologically available to humans upon ingestion; 
however it is debated whether the amount of HT required to elicit its potential biological 
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APPENDIX A – Safety Blood Draws 
 
Researchers performed safety blood analyses at baseline and at days 14, 28 and 39 of 
supplementation.  Baseline blood safety parameters were measured at the baseline Muscle 
Biopsy visit, and subsequent blood safety parameters were measured at days 8, 14, 28 and 39 of 
supplementation and compared to baseline measures to ensure that the study supplement was 
safe to consume.  For each safety blood draw, the subject reported to the laboratory in the 
morning after a 12 hr fast, during which only water was consumed.  If dietary, exercise, and 
health criteria were met, a researcher drew 15 ml blood from a forearm vein and sent the blood 
sample the same day to an off-site diagnostic laboratory (Quest Diagnostics, Irving, TX) to 
measure the following markers:   
 Lipid panel:  triglycerides, total cholesterol, high density lipoprotein, low-density 
lipoprotein (calculated), cholesterol/high density lipoprotein ratio (calculated), non-high 
density lipoprotein (calculated), very low density lipoprotein 
 Blood cell panel:  white blood cells, red blood cells, hemoglobin, hematocrit, mean cell 
volume, mean cell hemoglobin, mean cell hemoglobin concentration, red blood cell 
distribution width, platelets 
 Metabolic panel:  albumin, albumin/globulin ratio (calculated), alkaline phosphatase, 
alanine transaminase, aspartate transaminase, blood urea nitrogen/creatinine ratio 
(calculated), calcium, carbon dioxide, chloride, creatinine, globulin (calculated), glucose, 
potassium, sodium, total bilirubin, total protein, urea nitrogen 
 Lipase 
 Amylase 
 Hemoglobin A1c 
 Gamma-glutamyl transpeptidase (GGT) 
 Uric acid 
 Lactate dehydrogenase (LDH) 
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 Total creatine kinase (CK) 
 Phosphorus 
 
All results from the diagnostic laboratory were reviewed by the study physician within 48 
hr.  If abnormal blood results were observed by the study physician, the subject was asked to 
return to the laboratory for a blood re-draw.  The re-draw results were likewise sent to the 
diagnostic laboratory and reviewed by the study physician within 48 hr to determine if any 
persistent abnormalities were clinically significant.  The study physician did not observe any 
clinically-significant abnormalities during the course of the study that would warrant excusing a 








PGC-1α (% of std) 
 PLA LO HI 
Subject Base End Base End Base End 
1 3.2 6.5 11.1 5.5 5.0 7.9 
2 1.6 11.8 1.5 1.7 9.2 10.5 
3 4.2 6.0 4.6 6.8 6.5 6.4 
4 6.4 5.2 2.9 4.9 2.9 2.9 
5 5.3 4.6 1.7 1.5 3.2 3.1 
6 2.0 0.9 4.2 4.3 0.5 4.9 
7 4.8 6.1 2.1 3.8 3.4 3.2 
8 2.1 2.2 2.2 1.8 0.5 2.9 
9 4.0 4.3 8.5 8.7 3.8 1.6 
10 2.3 7.7 1.8 6.1 5.9 2.1 
11 8.6 6.8 1.3 0.6 8.2 16.2 
12 3.5 4.8 2.5 3.2 10.1 8.5 
13 3.6 3.5 5.9 5.5 4.5 4.6 
14 5.8 4.7 6.1 7.2 2.6 1.3 
15 6.4 6.6 6.2 7.3 6.3 3.5 
16 1.3 16.3 2.5 3.8 5.7 11.1 
17 4.5 10.3 7.5 8.4 0.9 3.7 
18 6.8 3.7 5.8 5.4 5.9 7.6 
19 7.0 5.8 4.0 5.9 2.5 1.8 
20   6.7 5.3 5.4 7.3 
21     1.2 5.1 
22     4.0 4.9 
MEAN 4.4 6.2 4.5 4.9 4.5 5.5 






α-tubulin (% of std) 
 PLA LO HI 
Subject Base End Base End Base End 
1 5.7 11.3 32.2 21.2 21.2 20.6 
2 42.9 41.0 3.1 4.7 4.7 23.8 
3 15.4 12.7 5.1 13.2 13.1 15.9 
4 12.7 13.9 9.6 13.5 13.5 6.3 
5 8.9 10.2 2.1 2.0 2.0 9.2 
6 5.2 2.7 12.3 7.7 7.7 8.5 
7 11.5 12.2 6.1 10.5 10.5 9.8 
8 4.2 4.2 7.7 7.9 7.9 4.4 
9 6.7 9.6 10.3 11.3 11.3 3.9 
10 4.6 9.9 2.8 9.7 9.7 4.3 
11 9.6 9.3 2.4 1.6 1.6 38.0 
12 6.9 10.8 4.7 5.3 5.3 20.6 
13 8.4 8.5 7.7 9.5 9.5 7.8 
14 10.3 4.7 10.7 11.8 11.8 2.3 
15 34.5 32.1 11.0 19.2 19.2 6.6 
16 31.4 73.7 5.7 6.3 6.3 17.0 
17 10.0 21.3 19.1 17.2 17.8 8.3 
18 7.9 5.9 6.7 29.6 29.6 18.5 
19 18.3 14.4 13.7 9.4 9.4 6.0 
20   11.2 12.2 12.2 27.0 
21     2.3 10.7 
22     8.4 11.3 
MEAN 13.4 16.2 9.2 11.2 10.7 12.8 












 PLA LO HI 
Subject Base End Base End Base End 
1 4.250 3.903 3.817 5.208 4.176 3.928 
2 9.164 7.963 4.858 3.742 3.182 5.329 
3 3.583 3.894 4.894 5.091 4.814 5.791 
4 5.469 3.753 4.301 4.553 3.258 3.961 
5 7.908 6.599 4.844 5.288 6.163 5.844 
6 5.577 5.219 4.260 5.577 7.417 7.101 
7 5.574 6.579 4.012 7.702 7.507 6.939 
8 3.862 4.897 4.538 4.353 4.983 6.545 
9 3.747 4.512 4.399 5.100 5.726 5.366 
10 4.534 6.058 1.765 5.482 6.592 7.151 
11 5.956 7.283 4.660 3.870 5.322 5.763 
12 5.860 5.550 5.454 6.362 6.348 6.998 
13 6.307 6.879 5.585 5.619 3.815 4.307 
14 7.202 5.254 5.857 5.155 5.300 6.590 
15 4.655 4.639 5.927 2.653 5.330 4.652 
16 5.648 5.012 5.701 5.760 4.348 5.857 
17 2.498 3.254 5.356 4.850 5.591 7.407 
18 6.054 6.500 3.954 4.306 3.977 3.714 
19 6.449 5.251 4.744 7.387 5.718 4.148 
20     6.957 6.842 3.797 6.676 
21       5.979 5.122 
22       5.047 5.904 
MEAN 5.489 5.421 4.794 5.245 5.200 5.686 











 PLA LO HI 
Subject Base End Base End Base End 
1 36.563 32.853 36.303 37.910 26.613 25.715 
2 60.864 53.360 22.968 32.714 19.435 32.819 
3 28.108 24.391 27.644 26.925 33.527 32.258 
4 27.784 22.296 22.448 23.636 16.688 17.882 
5 42.724 32.760 25.978 29.807 27.616 27.757 
6 22.629 24.394 35.269 31.071 39.400 49.143 
7 30.436 38.432 21.842 40.902 35.146 44.075 
8 21.023 34.867 21.564 22.005 26.876 32.113 
9 22.185 31.486 20.458 25.679 26.615 25.075 
10 18.836 23.866 5.706 24.185 33.302 44.654 
11 29.719 34.593 20.772 22.137 33.846 39.781 
12 28.389 31.907 27.584 32.973 30.464 30.503 
13 38.510 36.313 28.915 31.707 17.480 22.723 
14 35.559 28.673 28.225 29.372 25.771 29.988 
15 22.535 30.654 28.087 15.472 29.327 26.364 
16 27.241 33.972 26.931 32.882 34.044 34.848 
17 23.007 31.111 25.751 24.995 28.993 37.473 
18 26.620 27.800 23.388 29.657 23.239 19.294 
19 30.021 23.661 29.423 36.941 33.488 31.939 
20     35.917 34.418 32.431 40.004 
21       22.379 21.214 
22       21.374 25.180 
MEAN 30.145 31.441 25.759 29.269 28.093 31.400 









 PLA LO HI 
Subject Base Mid End Base Mid End Base Mid End 
1 3.52 3.69 3.28 3.71 3.52 3.82 2.4 2.19 2.23 
2 3.65 3.61 3.49 2.8 2.94 2.83 2.83 2.9 2.9 
3 3.18 3.11 3.09 2.27 2.49 2.17 3.56 3.45 3.66 
4 2.83 2.79 2.79 2.65 3.01 3.18 2.73 2.87 2.77 
5 3.52 3.69 3.58 3.52 3.72 3.66 2.92 2.85 2.68 
6 3.16 3.39 3.43 3.33 3.24 3.58 2.81 2.88 3.01 
7 3.00 2.90 3.04 3.47 3.6 3.55 2.96 3.4 3.23 
8 2.88 2.87 2.74 2.83 2.83 2.91 2.77 2.69 2.84 
9 2.86 3.33 2.84 2.9 3.03 3.09 2.92 3.02 3.16 
10 3.63 3.86 3.93 2.87 2.69 3.09 3.27 3.27 3.38 
11 4.48 4.60 4.65 3.28 3.13 3.27 4.03 4.1 3.9 
12 4.39 4.04 4.23 3.54 3.63 3.91 3.97 3.95 4.07 
13 4.20 4.40 4.26 4.04 3.7 3.69 3.42 3.42 3.45 
14 3.50 3.45 3.72 3.61 3.52 3.64 2.92 2.98 3.01 
15 3.82 3.73 3.98 2.66 2.82 2.86 4.09 3.86 3.68 
16 3.68 3.76 3.74 3.49 3.88 3.8 4.19 4.11 4.14 
17 2.71 3.03 2.91 2.96 2.93 3.1 4.72 4.96 5.26 
18 4.05 4.35 4.49 3.42 3.64 3.6 3.42 3.66 3.41 
19 4.67 4.45 4.46 3.75 3.77 3.76 3.47 3.45 3.63 
20       3.68 3.53 3.84 2.97 3.03 2.91 
21          3.85 3.63 3.67 
22          4.04 4.27 3.94 
MEAN 3.56 3.63 3.61 3.24 3.28 3.37 3.38 3.41 3.41 







VO2 at Lactate Threshold 
 
VO2 at Lactate Threshold (L O2•min
-1
) 
 PLA LO HI 
Subject Base Mid End Base Mid End Base Mid End 
1 1.96 1.98 1.67 1.69 2.36 1.77 2.11 1.44 1.44 
2 1.68 1.88 1.78 1.64 1.69 1.46 1.36 1.45 1.43 
3 1.59 1.52 1.68 1.45 1.57 1.68 1.94 1.55 1.66 
4 1.67 1.56 1.63 1.40 1.63 1.74 1.93 1.50 1.59 
5 2.41 2.52 2.04 1.17 1.96 2.20 1.75 1.80 1.68 
6 1.64 2.07 1.83 1.94 1.97 2.11 1.64 1.68 1.95 
7 2.06 1.30 1.84 1.75 1.56 2.23 2.03 1.85 1.91 
8 1.81 1.68 1.62 1.55 1.51 1.67 1.39 1.77 1.76 
9 1.96 1.95 1.82 1.98 1.92 1.83 1.90 1.66 1.75 
10 2.43 2.79 2.74 1.55 1.66 1.76 2.35 2.08 2.40 
11 3.21 3.18 3.56 1.73 1.79 1.88 2.71 2.63 2.29 
12 1.82 2.28 1.98 2.12 2.28 2.16 2.17 2.41 2.61 
13 2.48 2.43 2.45 2.43 2.67 2.93 1.79 1.71 1.76 
14 1.81 1.88 2.17 2.33 2.07 2.60 1.38 1.51 1.35 
15 2.36 2.77 2.79 1.74 1.77 1.76 2.59 2.45 2.58 
16 2.00 2.30 2.40 1.81 2.14 2.27 2.70 2.87 2.73 
17 1.29 1.45 1.63 1.48 1.35 1.41 2.78 2.77 2.73 
18 2.36 2.45 2.89 1.23 1.55 1.69 2.30 2.07 1.74 
19 2.75 2.65 2.78 2.16 2.29 2.22 2.21 2.07 2.05 
20       2.22 2.39 2.48 1.88 1.91 1.52 
21          2.08 2.36 2.27 
22          2.45 2.51 2.36 
MEAN 2.07 2.14 2.17 1.77 1.91 1.99 2.07 2.00 1.98 




RER at Steady State 
 
Respiratory Exchange Ratio (RER) at 65% VO2MAX 
 PLA LO HI 
Subject Base Mid End Base Mid End Base Mid End 
1 0.98 0.95 1.01 0.99 0.98 1.00 1.03 1.03 1.03 
2 1.01 1.02 1.02 1.07 1.01 1.01 1.05 1.06 1.07 
3 1.04 1.00 1.03 1.00 0.97 0.94 1.01 1.01 0.97 
4 1.03 0.97 1.03  1.01 0.98 1.01 0.98 1.05 
5 1.01 0.92 0.98 1.01 1.02 0.98 1.00 0.92 1.03 
6 1.00 0.98 0.95 1.04 0.97 0.98 1.04 0.96 0.99 
7 0.99 0.95 0.95 1.05 1.04 1.02 0.97 0.96 0.96 
8 0.93 1.01 1.02 1.02 1.01 1.02 1.02 1.03 1.02 
9 0.94 0.93 0.95 1.00 0.99 0.95 0.99 1.00 0.97 
10 0.97 1.02 0.98 1.01 1.02 0.99 0.92 0.95 0.95 
11 0.99 0.98 1.01 1.01 1.02 1.00 0.95 0.96 0.92 
12 1.04   1.06 0.96 0.97 0.97 0.96 0.97 0.93 
13 0.97 1.00 0.97 0.96 0.99 0.96 0.98 0.99 0.97 
14 0.97 0.97 0.99 0.96 0.96 0.97 1.04 1.04 1.00 
15 0.99   0.95 1.03 0.98 1.00 0.97 0.98 0.98 
16 0.95 0.96 0.95 1.02 0.98 0.97 0.96 0.95 0.97 
17 0.96 1.00 1.04 1.11 1.08 1.09 0.99 0.92 0.96 
18 0.96 0.97 0.90 1.01 1.02 1.02 1.03 0.99 0.98 
19 0.96 0.99 1.01 1.03 1.00 0.97 0.98 1.02 1.04 
20       0.98 0.97 1.00 1.04 1.03 1.03 
21          0.97 1.03 1.02 
22          1.00 0.99 1.00 
MEAN 0.98 0.98 0.99 1.01 1.00 0.99 1.00 0.99 0.99 





Time Trial Performance 
 
Time Trial time to completion (min) 
 PLA LO HI 
Subject Base Mid End Base Mid End Base Mid End 
1 39.90 39.45 38.88 37.90 37.68 36.30 56.87 53.72 52.50 
2 39.90 38.88 37.83 46.78 42.52 42.37 45.82 43.78 43.15 
3 39.80 38.92 39.13 46.53 43.30 50.15 38.23 37.98 39.40 
4 44.37 42.38 42.08 46.50 46.10 45.87 44.40 43.93 43.00 
5 35.68 35.42 34.78 38.42 38.25  42.62 41.02 39.88 
6 41.62 41.43 40.17 39.83 39.15 38.13 41.58 40.50 39.25 
7 43.42 43.00 40.20 43.23 42.37 44.45 42.48 40.95 38.93 
8 43.97 45.88 45.33 46.70 46.63 45.57 46.98 44.15 43.42 
9 41.13 40.85 40.53 44.85 41.33 40.32 41.23 39.98 38.75 
10 43.80 37.80 35.90 47.18 46.65 48.10 38.95 37.93 37.92 
11 34.68 33.72 33.10 43.88 40.35 39.73 35.98 35.55 34.97 
12 37.43   34.80 38.77 38.62 38.77 36.17 35.22 34.43 
13 36.73 36.57 36.20 38.73 38.32 37.97 38.33 38.30 38.23 
14 39.62 39.25 40.37 37.60 36.75 36.28 42.77 43.88 42.33 
15 37.80 38.40 37.27 45.25 41.97 43.90 37.68 36.12 36.93 
16 35.83 34.77 34.08 40.77 39.92 39.23 37.52 37.03 36.35 
17 42.45 41.82 40.95 48.65 47.25 46.77 36.07 35.02 33.70 
18 35.58 35.42 37.83 38.93 39.17 37.52  42.78 40.07 
19 35.30 34.43 33.20 36.12 35.82 35.42 44.18 47.48 43.82 
20       39.00 37.95 37.60 48.53 46.33 43.80 
21          39.00 38.78 38.48 
22          41.52 39.18 37.98 
MEAN 39.42 38.80 38.03 42.28 41.00 41.29 41.76 40.89 39.88 





Time Trial Blood Lactate 
 
Time Trial Blood Lactate (mmol/L) 
 PLA LO HI 
Subject Base Mid End Base Mid End Base Mid End 
1 2.7 3.6 2.7 5.8 7.1 8.1 2.7 2.7 7.8 
2 9.8 10.2 12.6 3.6 4.7 7.4 4.9 3.4 8.3 
3 4.8 5.0 5.6 1.8 2.3 1.4 5.0 4.7 3.7 
4 5.6 5.0 5.8 2.9 3.2 2.8 4.6 4.2 7.9 
5 6.8 4.8 8.2 5.1 6.8 4.8 6.5 7.5 10.9 
6 4.5 5.9 2.9 5.4 8.2 7.8 6.4 9.3 1.1 
7 6.0 3.9 6.2 7.4 5.1 3.2 4.2 9.2 7.4 
8 5.9 3.5 5.6 5.4 4.7 4.3 2.4 2.9 5.3 
9 3.2 2.7 2.8 6.4 7.2 13.3 5.4 8.4 8.4 
10 4.1 8.2 7.6 4.1 6.2 3.6 7.0 5.4 5.4 
11 8.7 9.2 8.8 4.2 7.6 6.9 6.0 8.9 9.3 
12 8.7   13.6 4.7 3.8 4.8 2.7 7.2 7.3 
13 8.6 8.7 6.2 4.0 7.6 4.2 7.1 8.0 8.2 
14 3.0 5.0 2.6 3.8 5.5 6.6 4.9 3.6 4.7 
15 3.8 2.9 3.5 2.9 6.4 7.1 5.4 4.8 7.4 
16 4.5 6.3 5.8 4.5 3.8 3.7 4.4 5.0 9.0 
17 6.4 3.7 2.1 5.3 5.6 4.9 6.8 4.9 8.2 
18 8.2 8.5 2.5 7.7  10.4  2.5 5.4 
19 3.9 7.9 12.8 12.6 9.7 9.2 2.0 1.7 3.1 
20       3.2 4.2 5.2 3.5 5.9 6.4 
21          6.2 5.3 5.7 
22          2.2 3.7 4.2 
MEAN 5.7 5.8 6.2 5.0 5.8 6.0 4.8 5.4 6.6 




Time Trial RPE 
 
Time Trial Rating of Perceived Exertion (Borg scale) 
 PLA LO HI 
Subject Base Mid End Base Mid End Base Mid End 
1 14 16 15 18 19 20 14 14 14 
2 18 17 16 13 15 15 14 13 15 
3 16 16 17 14 17 17 17 19 19 
4 15 15 15 13 16 13 16 17 16 
5 17 18 19 16 15 15 14 14 14 
6 17 16 17 16 18 17 14 15 16 
7 16 18 17 14 15 13 16 18 19 
8 16 17 17 17 15 17 13 14 16 
9 15 16 16 16 16 15 17 18 15 
10 17 18 19 15 15 14 17 17 18 
11 17 16 18 14 15 15 18 19 20 
12 18   18 14 15 15 14 15 16 
13 15 17 18 12 13 13 15 16 15 
14 14 16 17 17 17 18 15 15 14 
15 15 16 17 16 15 16 16 18 16 
16 15 17 19 15 15 15 16 16 16 
17 15 15 17 17 16 15 15 12 13 
18 13 13 16 14 16 16   12 13 
19 16 17 18 17 14 14 14 14 15 
20       15 14 16 17 15 14 
21             14 15 16 
22             15 16 16 
MEAN 15.7 16.3 17.2 15.2 15.6 15.5 15.3 15.5 15.7 
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